Objective:Present study was aimed to analyze the immunogenicity of recombinant Lugurus zona pellucida-3 protein (r-LZP3) expressed in E.coli,and to evaluate the efficacy of its antiserum to affect in vitro mouse sperm-egg binding.Methods:Female mouse were immunized using LZP3 DNA vaccine for priming,and boosted with r-LZP3 protein.The antibody response level of LZP3 antisera was determined by ELISA.The immunoreactivity and specificity of the anti-LZP3 antisera were tested by immunoblot, indirect immunofluorescence and immunohistochemistry using native mouse ZP.A sperm-zone pellucida binding assay was used to evaluate the efficacy of anti-LZP3 antisera to inhibit mouse sperm-egg binding in vitro.Results: The result of ELISA showed that LZP3 DNA vaccine was able to induce higher antibody titers in mouse.Antiserum could specifically recognize or bind to r-LZP3 protein expressed in E.coli and native mouse ZP in vitro.The LZP3 antisera and r-LZP3 protein also inhibited sperm-egg binding in vitro.Condusion:These results show that r-LZP3 protein is of strong immunogenicity.

Pharmaceuticals were chosen as the entry point to analyze the status and characteristics of China′s pharmaceutical exports. An export competitiveness evaluation system was comprehensively constructed by selecting the scale, quality and progress of international trade as three dimensions. Net exports, export contribution rate, international market share, display comparative advantage index, competitive advantage index, Michaely index and export advantage growth index as seven indices. In order to avoid the discrepancy caused by the different angles of each index, the indicators were abstracted into two comprehensive ones through principal component analysis, to measure the export competitiveness of the world′s leading countries and regions in pharmaceuticals import and export directly. The result shows that China′s exporting competitiveness of pharmaceuticals ranks the sixth among the 10 major import and export countries in the world. On this basis, dialectical reference is made from Switzerland with strong export competitiveness of pharmaceutical products, in order to promote the long-term development of the export of pharmaceutical products in China.

OBJECTIVE:To study the spatial distribution characteristics of pharmaceutical manufacturing industry in China. METHODS:According to public data of listed company,social network analysis method was used to analyze the data of listed companies in China's pharmaceutical manufacturing industry in respect of network density analysis(including overall network density and individual network density),network centrality analysis,cohesion analysis,core-edge analysis. The discussion and suggestion was put forward. RESULTS & CONCLUSIONS:As of Sept. 30th,2015,there were 168 listed companies of national A share listed pharmaceutical manufacturing industry. Analysis of social network analysis software showed that the density of spatial city association network in China's pharmaceutical manufacturing industry was 0.021 0,and the network was also much dispersed, among which Beijing,Tianjin and Shanghai had the largest individual network. In network centrality analysis,the point outdegree of the whole network was 1.604% and the point indegree was 1.761%. The point outdegree and point indegree of Beijing were all in the forefront. The betweenness centrality of Beijing,Shanghai,Tianjin and Shenzhen was in high level relatively,and the eigenvector centrality of Beijing,Tianjin,Shanghai,Kunming,Shenzhen and Guangzhou was in high level relatively. Results of cohesion analysis were more comprehensive,the cities in the network could be divided into 8 subgroups. The whole network showed a more obvious core-edge feature. So,the coordinated development of China's pharmaceutical manufacturing industry can be promoted by paying attention to play radiation driving role of industrial center city,promoting coordinated development of regional industry and forming industrial agglomeration network.

ABSTRACT OBJECTIVE：To analyze spatial distribution characteristics of pharmaceutical industry in the Yangtze RiverEconomic Belt，and to provide reference for regional pharmaceutical industry planning. METHODS：Based on the central analysis，agglomerated sub group analysis and secondary assignment program analysis of social network analysis，the industrial relevancebetween regional pharmaceutical industry and regional cities were studied（using the image matrix of agglomerated sub group），using regional pharmaceutical enterprises in the Yangtze River Economic Belt as the research object. RESULTS &CONCLUSIONS：The study involved 111 listed pharmaceutical companies in 82 regional cities，and 82 urban nodes formed aregional pharmaceutical industry distribution network，which could generate 8 urban cohesion subgroups，represented by Shanghai，Chengdu and Chongqing；Shanghai and Hangzhou in the Yangtze River Delta，Chengdu and Chongqing in the Chengdu and Chongqing economic circle have more advanced position in network centrality. The centrality of Shanghai was the highest（25.926），followed by Chongqing and Chengdu（both were 19.753）. It shows that the spatial distribution of the pharmaceuticalindustry in the Yangtze River Economic Belt shows a distribution pattern dominated by the Yangtze River Delta urbanagglomeration. At the same time，the Chengdu-Chongqing urban agglomeration also shows a greater influence. The regional citiesplay different roles in industrial development. Chongqing and Taizhou have shown stronger industrial radiation capabilities，while?Shanghai and Hangzhou have shown stronger industrial absorption capacity.

Objective To monitor the airbag pressure of artificial airway in mechanical ventilation patients, and to establish a mathematical model of airbag pressure decay, so as to explore the best interval of time for airbag pressure monitoring and provide a scientific basis to standardize the management of those patients.Methods Totals of 158 patients in respiratory intensive care unit ( RICU) with artificial airway were selected according to the upper limit of value, recommended by the guideline, the pressure of airbag was revised to 30 cmH2 O.The PORTEX pressure monitoring table was used and recorded every hour.Based on the recorded value, the mathematical model of airbag pressure decay was established using the curve fitting method, and then obtained the suitable interval of time for airbag pressure monitoring.Results Based on the recorded value and establishment of the mathematical model of airbag pressure decay, the optimum interval of time was 4.24 hours. If based on the lower limit of airbag pressure checked each hour, the optimum interval of time was 3.06 hours. Conclusions For the patients who have set up an artificial airway, the time for monitoring and correcting airbag pressure should be at least 4.24 hours.If based on a more safety point of view to prevent air leakage and the occurrence of complications, it should be at least 3.06 hours.